Literature DB >> 22628607

A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Evangelia Charmandari1, Amalia Sertedaki, Tomoshige Kino, Christina Merakou, Dax A Hoffman, Michael M Hatch, Darrell E Hurt, Lin Lin, Paraskevi Xekouki, Constantine A Stratakis, George P Chrousos.   

Abstract

CONTEXT: Aldosterone production in the adrenal zona glomerulosa is mainly regulated by angiotensin II, [K(+)], and ACTH. Genetic deletion of subunits of K(+)-selective leak (KCNK) channels TWIK-related acid sensitive K(+)-1 and/or TWIK-related acid sensitive K(+)-3 in mice results in primary hyperaldosteronism, whereas mutations in the KCNJ5 (potassium inwardly rectifying channel, subfamily J, member 5) gene are implicated in primary hyperaldosteronism and, in certain cases, in autonomous glomerulosa cell proliferation in humans.
OBJECTIVE: The objective of the study was to investigate the role of KCNK3, KCNK5, KCNK9, and KCNJ5 genes in a family with primary hyperaldosteronism and early-onset hypertension. PATIENTS AND METHODS: Two patients, a mother and a daughter, presented with severe primary hyperaldosteronism, bilateral massive adrenal hyperplasia, and early-onset hypertension refractory to medical treatment. Genomic DNA was isolated and the exons of the entire coding regions of the above genes were amplified and sequenced. Electrophysiological studies were performed to determine the effect of identified mutation(s) on the membrane reversal potentials.
RESULTS: Sequencing of the KCNJ5 gene revealed a single, heterozygous guanine to thymine (G → T) substitution at nucleotide position 470 (n.G470T), resulting in isoleucine (I) to serine (S) substitution at amino acid 157 (p.I157S). This mutation results in loss of ion selectivity, cell membrane depolarization, increased Ca(2+) entry in adrenal glomerulosa cells, and increased aldosterone synthesis. Sequencing of the KCNK3, KCNK5, and KCNK9 genes revealed no mutations in our patients.
CONCLUSIONS: These findings explain the pathogenesis in a subset of patients with severe hypertension and implicate loss of K(+) channel selectivity in constitutive aldosterone production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628607      PMCID: PMC3410272          DOI: 10.1210/jc.2012-1334

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  A diagnostic algorithm--the holy grail of primary aldosteronism.

Authors:  Gian Paolo Rossi; Teresa Maria Seccia; Achille C Pessina
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Authors:  Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

4.  A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III.

Authors:  Paolo Mulatero
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

5.  Familial forms broaden the horizons for primary aldosteronism.

Authors:  R D Gordon; M Stowasser
Journal:  Trends Endocrinol Metab       Date:  1998-08       Impact factor: 12.015

6.  Glucocorticoid-remediable aldosteronism.

Authors:  Florencia Halperin; Robert G Dluhy
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

7.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

8.  K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.

Authors:  Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 9.  TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation.

Authors:  S Bandulik; D Penton; J Barhanin; R Warth
Journal:  Horm Metab Res       Date:  2010-01-04       Impact factor: 2.936

Review 10.  Primary aldosteronism: an update on screening, diagnosis and treatment.

Authors:  Gian Paolo Rossi; Achille Cesare Pessina; Anthony M Heagerty
Journal:  J Hypertens       Date:  2008-04       Impact factor: 4.844

View more
  37 in total

Review 1.  Altered and dynamic ion selectivity of K+ channels in cell development and excitability.

Authors:  Haijun Chen; Franck C Chatelain; Florian Lesage
Journal:  Trends Pharmacol Sci       Date:  2014-07-09       Impact factor: 14.819

Review 2.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

3.  Channels and pumps in aldosterone-producing adenomas.

Authors:  Celso E Gomez-Sanchez
Journal:  J Clin Endocrinol Metab       Date:  2014-04       Impact factor: 5.958

Review 4.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

5.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

6.  Molecular and Electrophysiological Analyses of ATP2B4 Gene Variants in Bilateral Adrenal Hyperaldosteronism.

Authors:  Namita Ganesh Hattangady; Jessica Foster; Antonio Marcondes Lerario; Daniela Ponce-Balbuena; Juilee Rege; Silvia Monticone; William E Rainey; Paolo Mulatero; Tobias Else
Journal:  Horm Cancer       Date:  2020-01-30       Impact factor: 3.869

7.  A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome.

Authors:  Anli Tong; Guanghua Liu; Fen Wang; Jun Jiang; Zhaoli Yan; Dianxi Zhang; Yinsheng Zhang; Jun Cai
Journal:  J Clin Endocrinol Metab       Date:  2016-07-12       Impact factor: 5.958

Review 8.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

9.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof
Journal:  Mol Cell Endocrinol       Date:  2016-10-25       Impact factor: 4.102

Review 10.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.